title: Increased growth hormone responses to growth hormone releasing hormone and thyrotropin releasing hormone in patients with metastatic testicular cancer.
abstract: In 16 patients with metastatic testicular cancer and 10 age matched male control subjects growth hormone (GH) responses to growth hormone releasing hormone (GHRH; 1 microgram/kg body weight iv.) and thyrotropin releasing hormone (TRH; 200 micrograms iv.) were measured. Basal GH levels and GH levels following stimulation with GHRH or TRH were significantly increased in cancer patients compared to control subjects. 9 patients with testicular cancer were studied both in the stage of metastatic disease and after they had reached a complete remission. In complete remission GH responses to GHRH tended to decrease but the differences did not reach statistical significance. Our data suggest an alteration of hypothalamic and/or pituitary regulation of GH secretion in patients with metastatic testicular cancer.
authors.affiliation: II. Medizinische Universitätsklinik, Wien, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Pietschmann
authors.forename: R
authors.initials: R
authors.lastname: Kuzmits
authors.forename: G
authors.initials: G
authors.lastname: Schernthaner
mesh_terms: D000328:Adult; D004407:Dysgerminoma / Q000097:blood* / Q000473:pathology; D013006:Growth Hormone / Q000097:blood*; D013007:Growth Hormone-Releasing Hormone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009367:Neoplasm Staging; D012074:Remission Induction; D013736:Testicular Neoplasms / Q000097:blood* / Q000473:pathology; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*
chemical_list: D013973:Thyrotropin-Releasing Hormone; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone